



Universiteit
Leiden

The Netherlands

Imaging the (un)imaginable of the Barrier Immune system

Guo, N.

Citation

Guo, N. (2023, April 18). *Imaging the (un)imaginable of the Barrier Immune system*.


Retrieved from <https://hdl.handle.net/1887/3594146>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3594146>

Note: To cite this publication please use the final published version (if applicable).

A grayscale microscopic image of tissue, showing a dense cluster of cells in the upper right quadrant, with a more sparse, fibrous-looking area in the lower left. The overall texture is granular and complex.

Chapter 2

A 34-marker panel for Imaging Mass Cytometric analysis of human snap-frozen tissue

Nannan Guo¹, Vincent van Unen¹, Marieke E. Ijsselsteijn², Laura F. Ouboter³, Andrea E. van der Meulen³, Susana M. Chuva de Sousa Lopes⁴, Noel F. C. C. de Miranda², Frits Koning^{1,*}, Na Li^{1, 5 *}

¹Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands

²Pathology, Leiden University Medical Center, Leiden, The Netherlands

³Gastroenterology, Leiden University Medical Center, The Netherlands

⁴Anatomy, Leiden University Medical Center, Leiden, The Netherlands

⁵Key Laboratory of Zoonoses Research, Ministry of Education Institute of Zoonoses, College of Veterinary Medicine, Jilin University

*Equal contribution

Frontiers in Immunology 2020; 11: 1466.

Abstract

Imaging mass cytometry (IMC) is able to quantify the expression of dozens of markers at sub-cellular resolution on a single tissue section by combining a novel laser ablation system with mass cytometry. As such, it allows us to gain spatial information and antigen quantification *in situ*, and can be applied to both snap-frozen and formalin-fixed, paraffin-embedded (FFPE) tissue sections. Herein, we have developed and optimized the immunodetection conditions for a 34-antibody panel for use on human snap-frozen tissue sections. For this, we tested the performance of 80 antibodies. Moreover, we compared tissue drying times, fixation procedures and antibody incubation conditions. We observed that variations in the drying times of tissue sections had little impact on the quality of the images. Fixation with methanol for 5 min at -20° C or 1% paraformaldehyde (PFA) for 5 min at room temperature followed by methanol for 5 min at -20° C were superior to fixation with acetone or PFA only. Finally, we observed that antibody incubation overnight at 4° C yielded more consistent results as compared to staining at room temperature for 5 hours. Finally, we used the optimized method for staining of human fetal and adult intestinal tissue samples. We present the tissue architecture and spatial distribution of the stromal cells and immune cells in these samples visualizing blood vessels, the epithelium and lamina propria based on the expression of α -smooth muscle actin (α -SMA), E-Cadherin and Vimentin, while simultaneously revealing the colocalization of T cells, innate lymphoid cells (ILCs), and various myeloid cell subsets in the lamina propria of the human fetal intestine. We expect that this work can aid the scientific community who wish to improve IMC data quality.

Key terms: Imaging mass cytometry, IMC, Snap-frozen tissue sections, Human intestine, Mass cytometry

Introduction

In recent years, the development of a variety of single-cell technologies increased recognition of cellular heterogeneity both in physiological and pathological contexts. Single-cell technologies based on RNA sequencing and mass cytometry (CyTOF) have been utilized to investigate cellular heterogeneity and identify novel cellular subsets^{1, 2}, and to discover biomarkers with clinical value³. Single-cell mass cytometry employs antibodies conjugated to stable metal isotopes, mostly from the lanthanide series, and is currently able to analyze over 40 different markers simultaneously, allowing an in-depth analysis of immune subsets. However, when analyzing cells isolated from tissue, no spatial information on cell-cell interactions within the tissue is obtained. Imaging mass cytometry (IMC) is an extension of mass cytometry, which couples a laser ablation system with a mass cytometer⁴ and therefore has the ability to analyze up to 40 markers in a single tissue section. As such, IMC has the potential to simultaneously characterize the composition of the immune compartment, the spatial relationship between immune cells and stromal cells, and the interactions among immune subsets in tissue sections of choice.

2

Classical immunohistochemistry or immunofluorescence techniques for cell and tissue imaging provide high spatial resolution at subcellular resolution⁵, however, these suffer from limitations including the limited number of markers that can be used simultaneously and tissue auto-fluorescence⁶. IMC does not suffer from background interference as the read-out is provided by the presence of rare earth metals conjugated to antibodies which considerably increase the multiplexing capacity. The IMC laser system ablates the tissue in segments of one by one micrometer which are directed into the mass cytometer using a gas stream, then atomized and ionized followed by determination of the metal-isotope ion content in the on-line time-of-flight mass analyzer⁷. IMC thus offers significant advantages over the current imaging standards. However, care should be taken with the design of the antibody panels as there can be spillover detectable from one mass channel into other channels due to isotopic impurities of the rare metals, usually below 3%⁸, and a method has been developed to reduce spillover artifacts and improve the generation of high-quality data⁹. IMC is rapidly becoming widespread as it can aid both basic research and clinical practice^{10, 11}.

However, the use of IMC is still challenging due to the limited experience with the design and validation of antibody panels and the best tissue processing procedures and staining procedures compatible with the dozens of antibodies that are applied

simultaneously, especially with respect to snap-frozen tissue as most experience to date is with formalin-fixed paraffin-embedded (FFPE) tissue.

Here, we developed a 34 antibody panel for the analysis of snap-frozen tissues by IMC, which contains immune lineage and additional markers to distinguish immune cell subsets in addition to structural markers to reveal tissue organization. This panel can be used to obtain comprehensive spatial information on interactions both between immune cell subsets and between immune cell subsets and stromal components. Furthermore, we developed an optimized fixation and antibody incubation protocol to improve the IMC data quality. We anticipate that this optimized methodology will give guidance to the scientific community in using IMC on snap-frozen tissue to generate high-quality images.

Material and methods

Tissue samples

Fetal tissues were obtained from elective abortions with informed consent. The adult intestinal samples were collected from patients undergoing routine diagnostic endoscopies. Approval by the medical ethical commission of the Leiden University Medical Center (protocol P08.087) was obtained in accordance with the local ethical guidelines and the Declaration of Helsinki. The adult and fetal intestinal samples were embedded in optimal cutting temperature compound, snap-frozen in isopentane (VWR) and stored at -80° C.

Antibody validation and conjugation

Antigens were selected based on previously published single-cell mass cytometry and single-cell RNA sequencing data on the human fetal intestinal samples^{1, 12, 13}. Antibodies used for IMC are listed in Table 1. 16 of the 34 antibodies used in the current panel were directly purchased from Fluidigm, which were already conjugated with metals. For the remaining 18 antibodies, BSA-free and carrier-free formulations of antibodies were purchased from different suppliers and initially tested for performance by immunohistochemical staining (IHC) on human fetal intestine and tonsil. Subsequently, antibodies with an appropriate signal intensity were conjugated to lanthanide metals using the MaxPar Antibody Labeling Kit (Fluidigm) following the manufacturer's instructions. Post-conjugation, all antibodies were eluted in 100 µl W-buffer (Fluidigm) and 100 µl antibody stabilizer buffer (Candor Bioscience, Wangen im Allgäu, Germany) supplemented with 0.05% sodium azide.

A 34-marker panel for Imaging Mass Cytometric analysis of human snap-frozen tissue

Optimization of IMC Immunostaining protocol

Here, three variables were tested: 1) Drying condition of freshly prepared snap-frozen tissue sections; 2) Fixation procedures; and 3) Antibody staining conditions. For drying we compared 3 min at room temperature (RT) with 30 min at RT, and 1 hr at 60° C. For fixation we compared methanol for 5 min at -20° C, with 1% PFA for 5 min at RT, 1% PFA for 5 min at RT followed by methanol for 5 min at -20° C, acetone for 10 min at RT, and 4% PFA for 5 min at RT. For antibody incubation we compared 5 hr at RT with overnight at 4° C. We utilized one frozen sample to test each condition and a single antibody mix to stain all section slides. An overview of the experimental set up for the testing of the various conditions is provided in Table 2. All comparisons were performed simultaneously. The following is a step-by-step staining procedure of the IMC procedure utilizing snap-frozen tissue.

2

Material

- 5 µm fresh snap-frozen sections on silane-coated glass slides (VWR)
- Paraformaldehyde (1%, 4%)
- Methanol
- Acetone
- Superblock solution (Thermo Fisher Scientific)
- DPBS (Gibco)
- Wash buffer (DPBS supplemented with 0.05% Tween and 1% BSA)
- Metal-conjugated antibodies (Table 1)
- Intercalator-Ir (500 µM, Fluidigm)
- Milli-Q water
- Dako Pen (Thermo Fisher Scientific)
- Slide container, 5 slide capacity (VWR)
- Incubation chamber (humid, 4° C and RT)

Stepwise procedure for immunodetection

1. Cut the fresh frozen sections at 5 µm and mount them on silane-coated glass slides
2. Dry the tissue sections for 3 min at RT, 30 min at RT or 1 hr at 60° C
3. Fix the tissue slides without shaking as mentioned above
4. Rinse the slides once, followed by washing the slides twice for 5 min in a container of 5 slide capacity with 25 ml wash buffer
5. Rehydrate the slides for 5 min in container of 5 slide capacity with 25 ml DPBS
6. Wash the slides for 5 min in container of 5 slide capacity with 25 ml wash buffer

7. Use the Dako Pen to draw a circle around the tissue sections to create a barrier to contain the antibody solutions on the tissue sections
8. Apply 100 μ l superblock solution to each slide for 30 min at RT
9. Remove excess superblock solution by tapping on a tissue
10. Prepare the antibody cocktail by diluting the antibodies in wash buffer as described in Table 1
11. Add 100 μ l of the antibody cocktail to each section and incubate for 5 hr at RT or overnight at 4° C in a humid chamber
12. After the incubation, wash the sections three times for 5 min in container of 5 slide capacity with 25 ml wash buffer
13. Incubate the slides with 100 μ l 1:400 dilution of Intercalator-Ir in DPBS for 30 min at RT
14. Rinse the slides once, wash the slides for 5 min in container of 5 slide capacity with 25 ml wash buffer twice
15. Wash the slides for 1 min in container of 5 slide capacity with 25 ml Milli-Q water
16. Dry the slides with an air flow
17. Store the slides at 4° C until ablation on Hyperion


Imaging mass cytometry acquisition

Tissue acquisition was performed on a Helios time-of-flight mass cytometer coupled to a Hyperion Imaging System (Fluidigm). All IMC operation was performed as described using the Hyperion Imaging System (Fluidigm). Briefly, after flushing the ablation chamber with helium, tissues were ablated by a UV-laser spot-by-spot at a resolution of 1 μ m and a frequency of 200 Hz. Regions of interest (ROIs) with 1,000 μ m x 1,000 μ m were selected. We ablated 5~8 ROIs for each tissue section. All raw data were analyzed for marker intensity based on the maximum signal threshold, defines at the 98th percentile of all pixels in a single ROI using the Fluidigm MCD™ viewer (v1.0.560.2). To distinguish the signal from background, we used the Fluidigm MCD™ viewer to visualize our data, based upon which we determined the threshold for each marker individually (between 1 and 2 for majority of immune markers and between 1 and 3 for structural markers) to eliminate background.

Results

To develop the IMC antibody panel, we first evaluated the performance of an antibody panel previously developed for cell suspension mass cytometry¹. This revealed that 18 out of the 36 antibodies were suitable for IMC on snap-frozen

A 34-marker panel for Imaging Mass Cytometric analysis of human snap-frozen tissue



(Figure legend in next page)

2

Figure 1 Comparison of antibody and nuclear staining between different fixation procedures for IMC within a single tissue block. (A) Comparison of the staining intensity of each antibody depending on the fixation conditions, based on the maximum signal threshold in MCDTM viewer. Black bars indicate median $\pm$ IQR. Each gray dot represents an individual ROI. * $P < 0.05$ by Kruskal-Wallis test with Dunn's test for multiple comparisons. (B) The markers CD45 and CD3 are representative for the variations observed with the tested incubation conditions. The minimum signal threshold of 2 dual count was set for the nuclear staining, while that was 1.5 for the immune markers.

tissue. Subsequently we continued to select additional antibodies to phenotype immune cells and visualize the tissue structure. All candidate antibodies which required in-house conjugation with metals were initially tested for performance by conventional immunohistochemistry (not shown). Based on this we selected antibodies that displayed a clear signal-to-noise ratio for potential inclusion in the final IMC antibody panel. In total, 80 antibodies were tested, 43 of which performed well on frozen sections. Table 2 lists the 34 antibodies that were finally chosen for inclusion into the IMC antibody panel. Supplementary Table 1 provides information on the performance of the 46 antibodies that were not included in the panel. In order to ensure proper tissue adherence, we determined the influence of the time of drying for the freshly prepared tissue sections. We evaluated the staining obtained with each of the 34 antibodies on tissue sections that were either dried for 3 or 30 min at RT, or for 1 hr at 60 °C. Both visual inspection of the obtained images and comparison of the maximum signal threshold values for each antibody indicated that the staining intensity was comparable with all three drying conditions (Supplementary Figure 1A). We also observed that the signal-to-noise ratio was highly similar with the three tested conditions (Supplementary Figure 1B). Therefore, we conclude that the drying conditions tested are in principle all suitable for IMC on snap-frozen tissue sections.

As tissue fixation is required to preserve antigenic determinants in tissues we first evaluated the protocol provided by Fluidigm¹⁴. However, we observed that acetone fixation did not yield satisfactory results with respect to the quality of both the nuclear staining and the antibody staining (not shown). Therefore, we proceeded to test additional fixation procedures to optimize signal intensity and signal-to-noise ratio. We tested 5 conditions, using serial sections from a single tissue sample: methanol, 1% PFA, 1% PFA followed by methanol, acetone and 4% PFA and evaluated the staining obtained with the 34 antibodies individually (Figure 1A, B). We observed that none of the tested fixation conditions yielded optimal results for all antibodies in the panel. As expected, we observed inadequate nuclear staining with acetone, incompatible with proper cell identification and cell segmentation analysis (Figure 1B). Moreover, comparison of the maximum signal threshold

A 34-marker panel for Imaging Mass Cytometric analysis of human snap-frozen tissue




Figure 2 Comparison of antibody performance between two immunodetection conditions for IMC. (A) The staining intensity of each antibody at either 5 hr at room temperature or overnight at 4° C is shown, based on the maximum signal threshold in MCDTM viewer. Black bars indicate median±IQR. Each gray dot represents an individual ROI. ** $P < 0.01$ by Kruskal-Wallis test with Dunn's test for multiple comparisons. (B) The structural markers E-Cadherin, α-SMA and the immune markers CD7, CD45RA are representative for the variations observed with the tested conditions.


values for each antibody indicated that several markers performed relatively poor when either 1% or 4% PFA were used for fixation (e.g. CD161, CD163, CD3, CD7, CD68, HLA-DR, Vimentin, α -SMA) while fixation with methanol or 1% PFA followed by methanol yielded stronger signals. In addition, we observed higher background staining for immune markers (e.g. anti-CD45, clone HI30 and anti-CD3, Figure 1B) in both the acetone and PFA-only samples while the methanol and 1% PFA followed by methanol fixed samples provided superior antibody staining results (Figure 1B). However, the nuclear staining in the lamina propria of the intestine was slightly better in the PFA + methanol samples. Based on these observation, we conclude that fixation with methanol or with the combination of 1% PFA followed by methanol are both preferred for IMC immunodetection of snap-frozen samples.

As staining quality is strongly influenced by duration of and temperature during antibody incubation¹⁵, we tested two different incubation conditions for the individual antibodies in the 34-marker panel: 5 hr at RT or overnight at 4° C, after which the signal intensity and specificity were assessed by IMC for each antibody. We also determined the maximum signal threshold for all antibodies within several ROIs to compare the staining intensity between the two conditions. We found that the staining intensity of many antibodies were similar under both conditions, while a number of markers performed better either at 4° C (anti-CD20 and anti-E-Cadherin) or at RT (anti-CD45_1, and anti-CD45RA) (Figure 2A). However, we observed more variation in the maximum threshold values for the evaluated ROIs stained at RT compared to 4° C and for many antibodies higher background was observed at RT. For example, anti- α -SMA, anti-E-Cadherin and anti-CD7 yielded higher specific staining and lower background after overnight incubation at 4°C compared to a 5 h incubation at RT while several other antibodies performed equally well at both test conditions as observed with anti-CD45RA (Figure 2B). As incubation at 4°C yielded generally better results we decided to use this condition for validation of the full antibody panel.

We next applied the optimized protocol in which the tissue section was dried for 1 hr at 60 °C, followed by fixation with PFA + methanol and antibody panel incubation overnight at 4°C to stain a human fetal intestinal sample with the full 34-antibody panel which included structural tissue markers (Collagen I, E-Cadherin, α -SMA, Vimentin and D2-40) as well as markers to identify various cell types within the lymphoid and myeloid compartments (Table 1). Moreover, the panel allows for the visualization of additional features such as naïve and memory states (CD45RA/RO), cell division (Ki-67), tissue-residency (CD103 and CD69) and expression of cytokine receptors (e.g., CD122 and CD127) (Figure 3A, B, C).

A 34-marker panel for Imaging Mass Cytometric analysis
of human snap-frozen tissue

A




2

(B in next page)


Chapter 2

B



(C in next page)

A 34-marker panel for Imaging Mass Cytometric analysis
of human snap-frozen tissue



2

Figure 3 The optimized immunodetection of the 34-marker panel and cell nuclear staining in a single representative ROI for IMC on the human fetal intestine.

Based on the adjusted Threshold Min and Threshold Max in the MCDTM viewer (Table 3), the resulting images were analyzed. Collagen I immunodetection was used to delineate the extracellular matrix of the basement membrane which exhibited the highest staining intensity (Figure 3C). Vessels with smooth muscle lining were detected by the presence of α -smooth muscle actin (α -SMA, Figure 3C and Figure 4A), and CD31 and D2-40 staining (Figure 3A, C). The epithelium and lamina propria were distinguished as Vimentin-E-Cadherin⁺ and Vimentin+E-Cadherin⁻, respectively (Figure 4A). Cells of hematopoietic origin were identified with an anti-CD45 specific antibody, revealing that the majority of the immune cells were localized in the lamina propria (Figure 3). To define the spatial distribution of different immune subsets in the human fetal intestine, T cells (CD3⁺CD7⁺), innate lymphoid cells (ILCs, CD3⁻CD7⁺), B cells (CD20⁺), CD11c⁺HLA-DR⁺ myeloid cells, and macrophages (HLA-DR⁺CD163⁺), were identified and visualized in a single region of interest (Figure 4B,C). For comparison, the individual stains for DNA, the structural markers E-Cadherin, α -SMA, and Vimentin, as well as the immune markers CD3, CD7, CD20, CD11c, HLA-DR and CD163 are shown in Figure 4D. In Figure 4B a single CD20⁺ B cells is identified (cyan) while CD3⁺CD7⁺ T cells (yellow) and CD3⁻CD7⁺ ILCs (green) are present both as isolated cells and adjacent to each other (two boxed areas on the left side of the image, Figure 4B). In addition, a white CD11c⁺ myeloid cells was detected colocalized with a T cell (boxed area on the right side of the image, Figure 4B). Moreover, the visualization of HLA-DR and CD163 reveals the close association of HLA-DR⁺CD163⁺ macrophages (blue/cyan) with adjacent T cells and ILCs (two boxed area's on the left side of the image, Figure 4C), and several clusters of T cells and HLA-DR⁺ myeloid cells (Figure 4C). Thus, the optimized approach for snap-frozen tissue analysis with IMC presented here facilitates the simultaneous identification of multiple distinct cells types and distinct colocalization patterns thereof in a single image. In addition we applied the optimized staining protocol with the full antibody panel to two adult intestinal samples, one from a healthy control (Figure 5A) and another from a patient with inflammatory bowel disease (Figure 5B). Here we observed clear tissue structures based on E-Cadherin, α -SMA, Vimentin and DNA staining (Figure 5). Moreover, visualization of the immune lineage markers CD3, CD7, CD20, HLA-DR, CD163 and CD11c revealed the presence and distribution of lymphoid and myeloid immune cell subsets within the tissue context in a single section (Figure 5).

Discussion

We report the development of a 34-antibody panel and an optimized staining protocol for snap-frozen tissue sections for analysis with IMC. Based on staining

A 34-marker panel for Imaging Mass Cytometric analysis
of human snap-frozen tissue




Figure 4 Visualization of the tissue structure and detection of immune cell types in a single region of interest in the human fetal intestine by IMC. (A) Representative mass cytometry image of the fetal intestine showing the overlay of E-Cadherin (magenta), Vimentin (green) and α-SMA (red). (B-D) Identification of immune cell subsets: (B) T cells (CD3⁺CD7⁺), innate lymphoid cells (ILCs, CD3⁻CD7⁺) and B cells (CD20⁺); (C) myeloid cell (CD11c⁺) and macrophages (HLA-DR⁺CD163⁺). The arrows indicate different immune cell types, while the boxes indicate the interaction between ILCs, T cells, and myeloid cells. (D) Individual antibody stains.




Figure 5 Representative mass cytometry images of 2 adult intestines. (A) The adult intestinal sample from a healthy control. (B) The adult intestinal sample from a patient with inflammatory bowel disease.

intensity and signal-to-noise ratio, we compared different fixation procedures, drying time of the tissue sections and the impact of duration and temperature during the antibody incubation. In principle, IMC is applicable to both FFPE and snap-frozen tissue but most studies so far have used FFPE tissue. In contrast to FFPE, snap-frozen tissue samples do not require antigen retrieval, thus simplifying the immunodetection protocol. Moreover, antibodies that can be used with frozen tissue cannot always be employed with FFPE tissue and vice versa. Thus, it is useful to have both options available. Previously, Chang *et al.* have shown that acetone can be used for the fixation of frozen and FFPE tissue for IMC¹⁴. However, while we also observed that acetone fixation can be used, the low quality DNA

staining did not allow an optimal cell segmentation analysis. Therefore we compared several fixation procedures that identified methanol or a combination of 1% PFA and methanol as appropriate for snap-frozen samples. While the tested variations in drying condition of the tissue samples did not influence the outcome of the staining procedure, we observed that antibody incubation overnight at 4° C yielded optimal results.

We applied the 34-antibody panel to identify various stromal elements and a variety of immune cell subsets in the human fetal intestine. The localization of collagen I, Vimentin, E-Cadherin and α -SMA allowed the visualization of the major architecture of the tissue sample and distinction of the villi, crypts, basal membrane and lamina propria. Simultaneously, T cells, ILCs and various myeloid cell subsets could be identified as well as interactions between these cell types individually and in clusters of lymphoid and myeloid cells. Here, the specific co-localization of ILCs, T cells and myeloid cells in the lamina propria suggests that the ILCs may somehow modulate the interaction between the T cells and myeloid cells directly. Moreover, recent findings have shown that memory T cells are generated in the human fetal intestine and the specific co-localization of T cells and myeloid cells may ultimately reveal where such memory responses are initiated¹⁶. Here, additional markers in the antibody panel, like HLA-DR and Ki-67, will likely aid in the identification of activated T cells *in situ*.

In the present study we have used the MCD™ viewer software to visualize the images of the tissue sections. In addition cell segmentation approaches based on the identification of nuclei have been developed to aid in the visualization of IMC data^{17, 18} as well as computational approaches to identify and quantify cell-cell interactions like Imacyte and Histocat^{19, 20}. Together this allows for an in depth investigation of cellular interactions in a variety of tissues. Thus, IMC offers a major advantage over classical immunohistochemistry techniques which are limited by the numbers of markers that can be included simultaneously. Together with other studies that have developed antibody panels for FFPE tissue^{15, 21, 22} this sets the stage for detailed studies to determine immune heterogeneity and cell-cell interactions *in situ*, providing a novel layer of understanding of functioning of the immune system on tissues. We anticipate that our study will guide other researchers that wish to use IMC for analysis of tissue of choice. Here the conditions defined in the present study can be used as a starting point, however, we like to emphasize that every tissue has its own characteristics that may require further optimization for the tissue under investigation.

Ethics Statement

The studies involving human participants were reviewed and approved by Leiden University Medical Center_LUMC (Protocol P08.087). The patients/participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

Author contributions

NG, NL and FK conceived the study and wrote the manuscript. NG performed most experiments with the help of VvU. NG performed most of the analyses with the help of VvU, MEI, LFO, AEvdM and NFCCdM. SMCdSL provided human fetal tissues. All authors discussed the results and commented on the manuscript.

Funding

This research was supported by Leiden University Medical Center (NG, VU, MI, LO, AM, SC, NM, FK, and NL), and the China Scholarship Council (NG and NL). FK was supported by the collaboration project TIMID (LSHM18057-SGF) financed by the PPP allowance made available by Top Sector Life Sciences & Health to Samenwerkende Gezondheidsfondsen (SGF) to stimulate public-private partnerships and co-financing by health foundations that are part of the SGF.

Acknowledgments

We thank the Center for Contraception, Abortion and Sexuality (Leiden and The Hague) for collection and provision of fetal material, K. Lodder, T. van Herwaarden, M. Bialecka, and F. Wang for dissection of fetal tissues.


A 34-marker panel for Imaging Mass Cytometric analysis of human snap-frozen tissue

Reference

1. Li, N. et al. Mass cytometry reveals innate lymphoid cell differentiation pathways in the human fetal intestine. *J Exp Med* 215, 1383-1396 (2018).
2. de Vries, N.L. et al. High-dimensional cytometric analysis of colorectal cancer reveals novel mediators of antitumour immunity. *Gut* 69, 691-703 (2020).
3. Havel, J.J., Chowell, D. & Chan, T.A. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. *Nat Rev Cancer* 19, 133-150 (2019).
4. Chang, Q. et al. Imaging Mass Cytometry. *Cytometry A* 91, 160-169 (2017).
5. Lichtman, J.W. & Conchello, J.A. Fluorescence microscopy. *Nat Methods* 2, 910-919 (2005).
6. Davis, A.S. et al. Characterizing and Diminishing Autofluorescence in Formalin-fixed Paraffin-embedded Human Respiratory Tissue. *J Histochem Cytochem* 62, 405-423 (2014).
7. Giesen, C. et al. Highly multiplexed imaging of tumor tissues with subcellular resolution by mass cytometry. *Nat Methods* 11, 417-422 (2014).
8. Bandura, D.R. et al. Mass Cytometry: Technique for Real Time Single Cell Multitarget Immunoassay Based on Inductively Coupled Plasma Time-of-Flight Mass Spectrometry. *Anal Chem* 81, 6813-6822 (2009).
9. Chevrier, S. et al. Compensation of Signal Spillover in Suspension and Imaging Mass Cytometry. *Cell Syst* 6, 612-+ (2018).
10. Diamond, N. et al. A Map of Human Type 1 Diabetes Progression by Imaging Mass Cytometry. *Cell Metab* 29, 755-+ (2019).
11. Wang, Y.J. et al. Multiplexed In Situ Imaging Mass Cytometry Analysis of the Human Endocrine Pancreas and Immune System in Type 1 Diabetes. *Cell Metab* 29, 769-+ (2019).
12. Li, N. et al. Memory CD4(+) T cells are generated in the human fetal intestine. *Nat Immunol* 20, 301-312 (2019).
13. Li, N. et al. Early-Life Compartmentalization of Immune Cells in Human Fetal Tissues Revealed by High-Dimensional Mass Cytometry. *Front Immunol* 10, 1932 (2019).
14. Chang, Q., Ornatsky, O. & Hedley, D. Staining of Frozen and Formalin-Fixed, Paraffin-Embedded Tissues with Metal-Labeled Antibodies for Imaging Mass Cytometry Analysis. *Curr Protoc Cytom* 82, 12 47 11-12 47 18 (2017).
15. Ijsselstein, M.E., van der Breggen, R., Sarasqueta, A.F., Koning, F. & de Miranda, N.F.C.C. A 40-Marker Panel for High Dimensional Characterization of Cancer Immune Microenvironments by Imaging Mass Cytometry. *Front Immunol* 10 (2019).
16. Li, N. et al. Memory CD4(+) T cells are generated in the human fetal intestine. *Nat Immunol* 20, 301-+ (2019).
17. Sommer, C., Straehle, C., Kothe, U., Hamprecht, F.A. & the IEEE International Symposium on Biomedical Imaging: From Nano to Macro, I. Ilastik: Interactive learning and segmentation toolkit. *IEEE Comput. Soc. Conf. Comput. Vis. Pattern Recogn. Proceedings - International Symposium on Biomedical Imaging*, 230-233 (2011).
18. Jones, T.R. et al. CellProfiler Analyst: data exploration and analysis software for complex image-based screens. *Bmc Bioinformatics* 9 (2008).
19. Somarakis, A., Van Unen, V., Koning, F., Lelieveldt, B.P.F. & Holtt, T. ImaCytE: Visual Exploration of Cellular Microenvironments for Imaging Mass Cytometry Data. *IEEE Trans Vis Comput Graph* (2019).
20. Schapiro, D. et al. histoCAT: analysis of cell phenotypes and interactions in multiplex image cytometry data. *Nat Methods* 14, 873-876 (2017).
21. Carvajal-Hausdorf, D.E. et al. Multiplexed (18-Plex) Measurement of Signaling Targets and Cytotoxic T Cells in Trastuzumab-Treated Patients using Imaging Mass Cytometry. *Clin Cancer Res* 25, 3054-3062 (2019).
22. Singh, N. et al. Development of a 2-dimensional atlas of the human kidney with imaging mass cytometry. *Jci Insight* 4 (2019).



Supplementary Information



(Figure legend in next page)

A 34-marker panel for Imaging Mass Cytometric analysis
of human snap-frozen tissue

Supplementary Figure 1 Comparison of the impact of the drying time of tissue sections on immune marker performance. (A) The staining intensity of each antibody for different drying tissue conditions was determined, based on the maximum signal threshold in MCDTM viewer. Black bars indicate median±IQR. Each gray dot represents an individual ROI. *P<0.05 by Kruskal-Wallis test with Dunn's test for multiple comparisons. (B) The surface markers CD45 and CD3, and the intracellular marker Ki-67 are representative for the variations observed by changing drying time. The minimum signal threshold of 1~2 dual count was set for the immune markers.

Supplementary table 1 Antibody validation for exclusion in the 34-antibody panel for IMC on snap-frozen tissue sections.

	Antigen	Tag	Clone	Supplier	Cat. No	Suitable for IMC
1	CD1a	115In	010	Dako	M357101-2	Yes
2	CD24	198Pt	ML5	BD	555426	Yes
3	CD26	157Gd	BA5b	Biolegend	302702	Yes
4	CD30	158Gd	Ber-H2	Dako	M075101-2	Yes
5	FcεRIα	143Nd	AER-37 (CRA-1)	Biolegend	334602	Yes
6	FOXP3	142Nd	D608R	CST	12653BF	Yes
7	ICOS	143Nd	D6N8TYM	CST	CST89601BF	Yes
8	SOX6	158Gd	polyclonal	Abcam	ab30455	Yes
9	TCRαβ	141Pr	8A3	Thermo Fisher	TCR1151	Yes
10	CCR6	141Pr	G034E3	Fluidigm	3141003A	No
11	CCR7	115In	Y59	Abcam	ab221209	No
12	CCR7	159Tb	G043H7	Fluidigm	3159003A	No
13	CD103	155Gd	Ber-ACT8	Biolegend	350202	No
14	CD11b	209Bi	ICRF44	Fluidigm	3209003B	No
15	CD127	165Ho	AO19D5	Fluidigm	3165008B	No
16	CD127	168Er	EPR2955(2)	Abcam	ab180521	No
17	CD14	160Gd	M5E2	Fluidigm	3160001B	No
18	CD14	Qdot800	TüK4	Thermo Fisher	Q10064	No
19	CD142	194Pt	TF9-10H10	Thermo Fisher	MA1-83495	No
20	CD15	115In	W6D3	Biolegend	323035	No
21	CD16	148Nd	3G8	Fluidigm	3148004B	No
22	CD1a	142Nd	HI149	Sony Biotech	2100510	No
23	CD20	163Dy	2H7	Biolegend	302343	No
24	CD25	149Sm	2A3	Fluidigm	3149010B	No
25	CD34	142Nd	581	Biolegend	343531	No
26	CD74	157Gd	LN2	BD	555612	No
27	CD8b	166Er	SIDI8BEE	BD	14-5273	No
28	CD90	104Pt	5E10	BD	14-0909-82	No
29	C-Kit	143Nd	104D2	Fluidigm	3143001B	No
30	C-Kit	143Nd	D3W6Y	Fluidigm	37805BF	No
31	CRTH2	156Gd	BM16	Biolegend	350102	No
32	Eomes	165Ho	21Mags8	BD	14-4876-82	No
33	Granzyme B	141Pr	EPR20129-217	Abcam	ab219803	No
34	IgM	150Nd	MHM88	Biolegend	314527	No
35	KLRG-1	161Dy	REA261	MACS	120-014-229	No
36	NKp44	147Sm	P44-8	Biolegend	325102	No
37	NKp44	147Sm	253415	R&D System	MAB22491	No
38	NKp46	174Yb	n1D9	Abcam	ab14823	No
39	NKp46	174Yb	9E 2	Biolegend	331902	No
40	PD-1	175Lu	EH 12.2H7	Fluidigm	3175008B	No
41	RORyt	156Gd	AFKJS-9	BD	14-6988-82	No
42	SLPI	110Pd	31	Abcam	ab17157	No
43	Tbet	149Sm	D6N88	Fluidigm	13232BF	No
44	TCRγδ	152Sm	B1	Biolegend	331202	No
45	TCRγδ	152Sm	11F2	Fluidigm	3152008B	No
46	TIGIT	143Nd	MBSA430	BD	16-9500-82	No
Cell Signaling Technology (CST), Sony Biotechnology (Sony Biotech)						

2

Tables

Table 1 The 34-marker panel on the snap-frozen section for imaging mass cytometry.

	Antigen	Tag	Clone	Supplier	Cat. No	Dilution
1	CD45	89Y	HI30	Flui	3089003B	1/50
2	D2-40	115In	D2-40	BioL	916606	1/50
3	FOXP3	142Nd	D608R	CST	12653BF	1/50
4	CD69	144Nd	FN50	Flui	3144018B	1/50
5	CD4	145Nd	RPA-T4	Flui	3145001B	1/50
6	CD8a	146Nd	RPA-T8	Flui	3146001B	1/50
7	Collagen I	147Sm	Polyclonal	Millipore	AB758	1/100
8	α SMA	148Nd	1A4	CST	CST5685BF	1/200
9	CD31	149Sm	8 9C2	CST	CST3528BF	1/100
10	E-cadherin	150Nd	24 E 10	CST	CST3195BF	1/50
11	CD123	151Eu	6H6	Flui	3151001B	1/50
12	CD7	153Eu	CD7-6B7	Flui	3153014B	1/100
13	CD163	154Sm	GHI/61	Flui	3154007B	1/100
14	CD103	155Gd	EPR4166	Abcam	ab221210	1/50
15	CD127	156Gd	R34.34	Beckman	18LIQ494	1/50
16	CD122	158Gd	TU27	BioL	339015	1/25
17	CD68	159Tb	KP1	Flui	3159035D	1/200
18	CD5	160Gd	UCHT2	BioL	300627	1/25
19	CD20	161Dy	H1	Flui	3161029D	1/50
20	CD11c	162Dy	Bu15	Flui	3162005B	1/50
21	CD45	163Dy	D9M81	CST	13917BF	1/200
22	CD161	164Dy	HP-3G10	Flui	3164009B	1/50
23	CD117	165Ho	104D2	BioL	313202	1/50
24	Ki-67	166Er	D3B5	CST	CST 9129BF	1/200
25	CD27	167Er	O323	Flui	3167002B	1/50
26	HLA-DR	168Er	L243	BioL	307651	1/800
27	CD45RA	169Tm	HI100	Flui	3169008B	1/100
28	CD3	170Er	UCHT1	Flui	3170001B	1/100
29	CD28	171Yb	CD28.2	BioL	302937	1/50
30	CD38	172Yb	HIT2	Flui	3172007B	1/100
31	CD45RO	173Yb	UCHL1	BioL	304239	1/50
32	CD57	174Yb	HNK-1/Leu-7	Abcam	Ab212403	1/100
33	Vimentin	175Lu	D21H3	CST	CST5741BF	1/200
34	CD56	176Yb	NCAM16.2	Flui	3176008B	1/50
Fluidigm (Flui), Cell Signaling Technology (CST) and Biolegend (BioL)						

Table 2 The experimental set up of the testing of the various conditions.

Slide Nr	Slide Drying			Fixation					Panel Incubation	
	3 min	30 min	1 hr	Methanol	1% PFA	1% PFA + methanol	Acetone	4% PFA	5 hr at RT	Over-night at 4° C
1	+	-	-	-	-	+	-	-	-	+
2	-	+	-	+	-	-	-	-	-	+
3	-	+	-	-	+	-	-	-	-	+
4	-	+	-	-	-	+	-	-	-	+
5	-	+	-	-	-	-	+	-	-	+
6	-	+	-	-	-	-	-	+	-	+
7	-	+	-	-	-	+	-	-	+	-
8*	-	-	+	-	-	+	-	-	-	+

* Conditions applied to slide #8 represent the optimal staining protocol.

A 34-marker panel for Imaging Mass Cytometric analysis
of human snap-frozen tissue

Table 3 The signal-to-noise ratio of individual antibody under optimal staining protocol.

Antigen	Channel	Threshold Min	Threshold Max	Signal-to-noise ratio
CD3	170Er	1.00	17.94	17.94
CD4	145Nd	1.50	5.41	3.61
CD5	160Gd	1.50	4.17	2.78
CD7	153Eu	1.50	21.97	14.65
CD8a	146Nd	1.50	4.60	3.07
CD11c	162Dy	1.00	4.42	4.42
CD20	161Dy	2.00	5.08	2.54
CD27	167Er	1.00	4.93	4.93
CD28	171Yb	1.00	3.99	3.99
CD31	149Sm	2.00	18.62	9.31
CD38	172Yb	1.50	12.01	8.01
CD45_1	89Y	1.50	9.66	6.44
CD45RA	169Tm	2.00	32.74	16.37
CD45RO	173Yb	3.00	17.60	5.87
CD56	176Yb	5.00	61.80	12.36
CD57	174Yb	5.00	22.25	4.45
CD68	159Tb	5.00	66.47	13.29
CD69	144Nd	1.50	4.20	2.80
CD103	155Gd	1.50	4.16	2.77
CD117	165Ho	1.00	4.58	4.58
CD123	151Eu	1.50	6.46	4.31
CD127	156Gd	2.00	4.32	2.16
CD161	164Dy	1.50	7.42	4.95
CD163	154Sm	2.00	23.10	11.55
Collagen I	147Sm	3.00	46.60	15.53
D2-40	115In	3.00	6.56	2.19
Vimentin	175Lu	5.00	94.23	18.85
E-cadherin	150Nd	1.50	7.89	5.26
HLA-DR	168Er	3.00	41.36	13.79
Ki-67	166Er	2.00	11.69	5.85
α-SMA	148Nd	3.00	46.20	15.40
CD122	158Gd	1.00	3.48	3.48
DNA1	191Ir	3.00	44.85	14.95
FOXP3	142Nd	2.00	3.10	1.55
CD45_2	163Dy	2.00	14.10	7.05
DNA2	193Ir	3.00	76.37	25.46

*The Threshold Max represents signal energy, while the Threshold Min represents noise energy for per marker in MCD™ Viewer. So Signal-to-noise ratio = Threshold Max / Threshold Min

2

